Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership711,762 shares
Latest Disclosed Value $ 93,753,135
Dimensional Fund Advisors Lp reports 0.66% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 711,762 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $93,753,135 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 716,475 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -0.66% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 711,762 -4,713 -0.66 93,753 -7.73 0.0042
2026-02-12 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 716,475 6,353 0.89 101,612 1.93 0.0213
2025-11-12 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 710,122 25,683 3.75 99,686 15.88 0.0214
2025-08-12 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 684,439 68,803 11.18 86,028 26.33 0.0199
2025-05-13 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 615,636 65,479 11.90 68,099 -9.32 0.0169
2025-02-13 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 550,157 26,525 5.07 75,101 24.48 0.0180
2024-11-07 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 523,632 50,703 10.72 60,331 -7.32 0.0146
2024-08-09 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 472,929 147,907 45.51 65,097 45.22 0.0170
2024-05-10 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 325,022 -11,514 -3.42 44,827 1.09 0.0121
2024-02-07 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 336,536 5,907 1.79 44,343 19.19 0.0129
2023-11-09 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 330,629 -5,535 -1.65 37,205 17.36 0.0122
2023-08-09 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 336,164 15,682 4.89 31,701 -2.27 0.0101
2023-05-12 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 320,482 -23,028 -6.70 32,435 79,009.76 0.0109
2023-02-09 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 343,510 -14,029 -3.92 41 -99.89 0.0121
2022-11-10 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 357,539 2,474 0.70 37,967 9.69 0.0146
2022-08-12 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 355,065 -62,539 -14.98 34,612 -11.59 0.0124
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 417,604 117,422 39.12 39,148 53.13 0.0121
2022-02-09 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 300,182 12,225 4.25 25,565 -7.43 0.0077
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 287,957 16,925 6.24 27,616 4.70 0.0089
2021-08-12 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 271,032 14,090 5.48 26,376 5.63 0.0084
2021-05-14 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 256,942 2,761 1.09 24,969 2.49 0.0083
2021-03-08 2020-12-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 254,181 11,612 4.79 24,362 4.43 0.0088
2021-02-11 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 254,181 11,612 24,362 8,798.2595
2020-11-12 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 242,569 65,787 37.21 23,329 8.15 0.0099
2020-08-13 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 176,782 12,752 7.77 21,571 51.89 0.0095
2020-05-14 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 164,030 -11,848 -6.74 14,202 -24.88 0.0074
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 175,878 -4,315 -2.39 18,905 16.43 0.0069
2019-11-12 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 180,193 -1,375 -0.76 16,237 5.94 0.0063
2019-08-13 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 181,568 10,257 5.99 15,327 1.58 0.0060
2019-08-12 2019-03-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 171,311 -1,946 -1.12 15,089 21.99 0.0060
2019-05-10 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 171,311 -1,946 15,089
2019-02-26 2018-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 173,257 6,149 3.68 12,369 -39.79 0.0056
2019-02-13 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 173,257 6,149 12,369
2018-11-13 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 167,108 -19,904 -10.64 20,542 11.82 0.0078
2018-08-10 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 187,012 -5,252 -2.73 18,371 15.22 0.0073
2018-05-11 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 192,264 270 0.14 15,944 7.05 0.0066
2018-02-12 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 191,994 10,243 5.64 14,894 33.76 0.0062
2017-11-13 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 181,751 5,554 3.15 11,135 37.38 0.0049
2017-08-11 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 176,197 10,782 6.52 8,105 13.18 0.0037
2017-05-12 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 165,415 -538 -0.32 7,161 11.51 0.0034
2017-02-09 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 165,953 4,428 2.74 6,422 -21.48 0.0032
2016-11-10 2016-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 161,525 18,093 12.61 8,179 25.46 0.0044
2016-08-09 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 143,432 10,901 8.23 6,519 24.43 0.0038
2016-05-13 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 132,531 -1,772 -1.32 5,239 -31.04 0.0031
2016-02-10 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 134,303 9,793 7.87 7,597 53.44 0.0047
2015-11-13 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 124,510 11,938 10.60 4,951 -7.89 0.0032
2015-08-14 2015-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 112,572 48,472 75.62 5,375 111.12 0.0033
2015-05-14 2015-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 64,100 64,100 83.79 2,546 445.18 0.0016
2013-11-13 2013-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -34,877 -100.00 0 -100.00
2013-08-15 2013-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 34,877 34,877 467 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.